Serum VEGF as a significant marker of treatment response in hodgkin lymphoma.
Pediatr Hematol Oncol
; 24(2): 111-5, 2007 Mar.
Article
en En
| MEDLINE
| ID: mdl-17454776
ABSTRACT
This pilot study aimed at determining serum VEGF levels (S-VEGF) at diagnosis and at restaging in children with Hodgkin lymphoma, and investigating whether this parameter provides prognostic information for remission after 2 courses of chemotherapy. PET-CT fusion was performed to assess response to treatment. Changes in S-VEGF levels were found to correlate with response to treatment for most of the children. This provides a rationale for exploring clinical interest in S-VEGF measurements in a larger group of children with Hodgkin lymphoma, and using the test for clinical trials of anti-angiogenic therapies.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedad de Hodgkin
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Biomarcadores de Tumor
/
Factor A de Crecimiento Endotelial Vascular
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Pediatr Hematol Oncol
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Año:
2007
Tipo del documento:
Article
País de afiliación:
Israel